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Summary Fifty years ago, Andreas Rett described
a disorder in 22 females featuring prominent re-
gression of fine motor and communication skills,
cognitive impairment, stereotypic movements, peri-
odic breathing, and gait abnormalities. This disorder
became known as Rett syndrome (RTT) following
the report of Hagberg et al. in 1983. Although RTT
was scarcely recognized at that time in the United
States, here the efforts of Rett and Hagberg led to
rapid progress in recognition and diagnosis, a clearer
understanding of its clinical and pathological under-
pinnings, and, ultimately, identification of mutations
in the methyl-CpG-binding protein 2 (MECP2) gene
as the primary cause of this unique and challenging
neurodevelopmental disorder. Thereafter, a natural
history study and critical translational research in
animal models paved the way for potential disease-
modifying agents to be assessed in human clinical
trials. To be successful, the energies of the interna-
tional community at all levels, including researchers
in clinical and basic science, funding agencies, phar-
maceutical companies, patient advocates, and, above
all, parents and their children are essential. Other-
wise, hopes for effective treatment, if not, a cure, will
remain unfulfilled.
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Fortschritte beim Rett-Syndrom – von der
Entdeckung zu klinischen Studien
Zusammenfassung Vor genau 50 Jahren beschrieb
Andreas Rett eine Erkrankung bei 22 Mädchen mit
auffallender Regression feinmotorischer und kommu-
nikativer Fähigkeiten, kognitiven Defiziten, stereoty-
pen Bewegungsmustern, periodischer Atmung und
Gangauffälligkeiten. Diese Erkrankung wurde nach
einer Veröffentlichung durch Hagberg et al. 1983 als
Rett-Syndrom bekannt. Obwohl das Syndrom zu je-
ner Zeit in den USA kaum bekannt war, führten die
Leistungen von Rett und Hagberg rasch zu vermehr-
ter Erkennung und Diagnosestellung, einem klare-
ren Verständnis der klinischen und pathologischen
Grundlagen und schlussendlich der Identifikation
von Mutationen im Methyl-CpG-binding-Protein-
2(MECP2)-Gen als primärer Ursache dieser besonde-
ren, herausfordernden neurologischen Entwicklungs-
störung. Danach ebneten eine Longitudinalstudie
zum natürlichen Krankheitsverlauf und entscheiden-
de Untersuchungen am Mausmodell den Weg für
die Erforschung potenziell krankheitsmodulierender
Substanzen in klinischen Studien. Für die Aussicht
auf Erfolg ist der Zusammenschluss aller Energien auf
internationaler Ebene wichtig – unter Einbezug der
Wissenschaftler in Klinik und Grundlagenforschung,
der Forschungsförderung, der pharmazeutischen In-
dustrie, von Patientenvertretern und vor allem von
Eltern und betroffenen Kindern. Andernfalls wird
der Wunsch nach effektiver Behandlung, wenn eine
Heilung schon nicht möglich ist, nicht in Erfüllung
gehen.
Schlüsselwörter Andreas Rett · Rett-Syndrom ·MECP2 ·
Verlaufsstudie · Klinische Studien
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Introduction
In 1965, Andreas Rett, a neuropediatrician in Vienna,
published the first report of a neurodevelopment
disorder involving females with early onset of de-
velopmental delay followed by frank regression, loss
of communication and fine motor skills, and the
appearance of stereotypic hand movements and pe-
riodic breathing during wakefulness [1]. Dr. Rett
attempted to ascertain and promote recognition of
similar features by other physicians throughout cen-
tral Europe with little success. Around the same time,
Bengt Hagberg, a child neurologist in Uppsala, was
recognizing the same constellation of clinical charac-
teristics in females from throughout Sweden, although
these two clinicians did not meet directly for another
15–20 years. In a series of laboratory studies looking
for a metabolic marker for this disorder, Rett had re-
ported elevated blood ammonia levels and published
these results in 1977 in the Handbook of Clinical
Neurology related to hyperammonemias [2]. During
this intervening period, Hagberg was discussing this
disorder with other child neurologists throughout
Europe, recognizing the clinical similarities, but also
failing to note the same blood ammonia findings as
described by Rett. At that point and with the enthu-
siastic participation of Jean Aicardi, Karin Dias, and
Ovidio Ramos, Hagberg began to prepare a paper on
35 females with this disorder from Sweden, France,
and Portugal. However, when he became aware that
blood ammonia results identified in Vienna were spu-
rious, and following a chance meeting with Rett in
Toronto in 1981, Hagberg decided to call this disorder
“Rett syndrome”. The paper appeared in the Annals of
Neurology in 1983, and suddenly child neurologists,
neuropediatricians, and geneticists around the world
were alerted to the existence of this new and unique
neurodevelopmental disorder [3]. Hagberg continued
to reveal additional findings, including developing
a staging system for RTT [4], identifying variant forms
of RTT [5], and leading the way first with initial criteria
development in 1984 [6] and then with their revision
in 2002, following the identification of mutations in
MECP2 [7].
In the United States, scarcely anyone knew about
this disorder prior to the Hagberg et al. paper [3].
Mary Coleman, a child neurologist in Washington
DC, had attended a meeting in Paris and learned of
Rett syndrome (RTT). Vanja Holm, a neuropediatri-
cian from Seattle, learned of this disorder on a visit
to Sweden. For myself, a pediatrician in Houston,
who suspected the disorder based on the Annals of
Neurology paper, referred a girl to the child develop-
ment clinic at Texas Children’s Hospital where I was
the child neurologist. The diagnosis of RTT was con-
firmed on examination of this young female and,
following a meeting with other child neurologists at
Baylor, five additional girls with RTT were identified
within the next few months. As the result of questions
raised by the parents of the first girl, contact was made
with both Bengt Hagberg and Andreas Rett, and an
invitation was received to attend the RTT meeting in
Vienna in 1984. Dr. Holm and Dr. Hugo Moser from
the Kennedy Krieger Institute (KKI) also attended.
This international meeting provided remarkable stim-
ulus for the expansion of studies on RTT throughout
the world. Subsequent meetings in 1986 and 1988
served to expand clinical, laboratory, and patholog-
ical studies attempting to elucidate metabolic and
genetic signals characteristic of RTT. Importantly, the
1984 meeting provided the opportunity for devel-
opment of diagnostic criteria (see above) that were
critical to the field going forward.
Initial developments in the US
In 1984, a RTT clinic was formed at Baylor together
with Daniel Glaze, Huda Zoghbi, and Dawn Arm-
strong, and other clinics emerged at the KKI in Balti-
more, in San Diego, and in Portland (Oregon). At the
same time, the International Rett Syndrome Associa-
tion (IRSA), a vital patient advocacy group, was cre-
ated by Kathy Hunter, Gail Smith, and Jane Brubaker.
This proved critical from several perspectives. First,
IRSA resulted in a focal point for parents, other care-
givers, and interested physicians to meet. Second,
Andreas Rett was invited to visit the US on several
occasions to provide consultation with physicians
and to examine and confirm diagnoses in affected
individuals. Third, Congressman Steny Hoyer from
Maryland was sufficiently moved by the situation to
promote legislation providing for research funds from
the National Institutes of Health (NIH). With that,
program projects were awarded to Baylor and to KKI,
markedly increasing research activities.
Among the initial reports that emerged were the
recognition of abnormalities in biogenic aminemetab-
olites in cerebrospinal fluid [8], neurophysiologic
abnormalities related to seizures [9] and periodic
breathing [10], and pathological investigations led by
Dr. Armstrong that revealed the brain to be smaller
than normal, to have reduced melanin pigmentation
in substantia nigra and other pigmented regions, and,
at the microscopic level, a reduction in neuronal size
and synaptic complexity with specific alterations in
dendrites [11–18]. What was not found was evidence
of a progressive neurodegenerative process. This last
feature suggested that RTT was a neurodevelopmental
abnormality that could be potentially reversible with
the proper strategies.
The etiology of RTT was considered by many to be
genetic, based on the exclusive occurrence, at least at
that time, of RTT in females, suggesting an X-linked,
dominant disorder. However, the efforts to identify
a biochemical or metabolic fingerprint greatly ham-
pered further understanding. At Baylor, Dr. Zoghbi
was then engaged in training in molecular genetics
and was encouraged to pursue studies into a molec-
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ular etiology for RTT. Interestingly, the presence of an
autosome–X chromosome translocation in one of the
first children evaluated allowed a large portion of the
X-chromosome to be excluded [19]. Gradually, the
area of interest was narrowed to Xq28 by a series of
studies from the rare instances of familial involvement
[20, 21]. In this regard, the general failure of recur-
rence in families and the X-linked dominant nature
suggested that a mutation, if one could be identified,
would result from a germline de novo mutation in
the father [22]. Although this idea was questioned
by some [23], the molecular search continued and
in 1999 a mutation in the methyl-CpG-binding pro-
tein 2 (MECP2) gene, located at Xq28, was identified
by Ruthie Amir [24] working in the Zoghbi laboratory.
Subsequently, these findings were confirmed in multi-
ple laboratories throughout the world [25–28]. Recog-
nition of males with RTT and both females and males
with MECP2 mutations were now confirmed [29, 30].
Males with RTT were the result of the co-occurrence
of Klinefelter syndrome (47XXY) [31–34] or somatic
mosaicism [35]. Familial occurrences were associated
with maternal mutations in which the transmitting fe-
male was either normal or had mild learning difficul-
ties or cognitive impairment [36–39]. Further on, with
this new information a number of laboratories began
to examine the role of MECP2 in brain development
and function. Interestingly, MECP2 had been well-de-
scribed in tumor biology for more than 10 years prior
to this linkage with RTT, due to its possible relation-
ship to methyl-binding domains in DNA [40–50]. Lab-
oratory studies have persisted and expanded over the
years to include potential disease-altering therapies
and possible genetic intervention to provide a more
fundamental curative avenue. In this regard, the stud-
ies of Guy et al. in a mutant mouse indeed showed
that if a normal gene were in place, near-normal re-
covery of function was possible [51].
At the same time, efforts in support of research into
the clinical and laboratory bases for rare diseases had
been enabled at the NIH through congressional man-
date. As a result, the Rare Disease Clinical Research
Network was formed and initial funding became avail-
able in the early 2000s. This resulted in the funding of
a natural history study (NHS) regarding RTT that has
been refunded twice and now, in its third iteration,
is addressing RTT, MECP2 duplication disorders, and
other RTT-related disorders including CDKL5, FOXGL,
and individuals with MECP2 mutations, both females
and males, who do not meet the diagnostic criteria for
RTT. To date, data from more than 1200 participants
evaluated in the first 11 years of the NHS have been
published and several additional topics are being an-
alyzed for submission. The current NHS study is con-
tinuing to gather information on the natural history
of the above mentioned disorders, collecting biologic
samples for possible detection of a biomarker, and in-
vestigating the event-related potentials of hearing and
vision (auditory brainstem and visual evoked poten-





A period of regression followed by stabilization and recov-
ery:
1. All main and all exclusion criteria





1. A period of regression followed by stabilization and
recovery
2. At least 2 of 4 main criteria and 5 of 11 supportive
criteria
Main criteria 1. Partial or complete loss of acquired purposeful hand
skills
2. Partial or complete loss of spoken language
3. Dyspraxic gait or inability to ambulate
4. Stereotypic hand movements: hand mouthing, hand
wringing/clasping, hand clapping, or finger rubbing
Exclusion
criteria
1. Brain injury: peri- or postnatal trauma, neurometabolic
disease, or severe infection involving neurological function
2. Grossly abnormal psychomotor development in first




1. Periodic breathing during wakefulness
2. Bruxism while awake
3. Altered sleep pattern
4. Abnormal muscle tone
5. Peripheral vasomotor disturbance
6. Scoliosis/kyphosis
7. Growth failure
8. Small cool/cold hands and/or feet
9. Inappropriate laughing or screaming spells
10. Delayed or diminished response to pain
11. Intense eye communication or “eye pointing”
tials). One of the initial outcomes of the NHS was
validation of the revised consensus criteria of 2010
following the convening of an international panel of
clinicians [52, 53]. These modifications simplified the
criteria and provided a distinction for their applica-
tion in classic and variant or atypical RTT (Table 1).
A multisystem problem
Despite the primary involvement of the central ner-
vous system (CNS), RTT is a multisystem problem. In
addition to brain growth, stereotypies, epilepsy, peri-
odic breathing, sleep, and other problems directly re-
lated to the CNS, multiple other systems are affected,
including growth and nutrition, the gastrointestinal
tract, and pubertal development. Overall, longevity
is reduced by about one third compared to typically
developing females. These aspects are discussed in-
dividually below, along with other important clinical
features.
Developmental skills
The acquisition of developmental skills was long sus-
pected of being abnormal, although specific data had
been lacking. As such, early development had been
characterized as “apparently” normal. Beginning with
the initial studies of Einspieler and Marschik taking
advantage of video recordings during infancy, sub-
stantial deviations from normal were noted [54–60].
Data from the NHS confirmed these findings and ex-
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tended them to include individuals with both classic
and atypical or variant RTT [61]. Longitudinal assess-
ments in the NHS allowed careful analysis of develop-
ment over time. Early developmental skills are gen-
erally acquired, but many of these skills are acquired
later than normal by most. Gross motor and receptive
language acquisition is much better than fine motor
and expressive language skills. Themore complexmo-
tor and communication skills such as managing stairs,
riding a tricycle, or demonstrating facility with read-
ing or mathematics are delayed or absent. Clinical
severity is less in those acquiring more skills. Better
outcomes are associated with specific mutations, as
described below.
Epilepsy
The electroencephalogram (EEG) pattern is generally
abnormal by age 3 years, with slowing of normal back-
ground and epileptiform wave patterns, often worse
during sleep. Seizures may be focal, generalized, or
atypical absence, and will occur in more than 85%
by age 16 [62]. However, the frequency of seizures
at any given age is highly variable, requiring medica-
tion for appropriate management in 35–40%. Video-
EEG monitoring is often required for differentiation
of seizures from nonepileptic behaviors. Typically,
the EEG becomes less epileptiform after age 20 and
seizures may abate significantly. Conversely, premen-
strual seizures (catamenial epilepsy) may be an issue
that requires chronic medication or short-term cover-
age with a long-acting benzodiazepine such as clon-
azepam.
Genotype–phenotype correlation
Definite genotype–phenotype correlations are noted
with important caveats [63–65]. For both classic
and atypical RTT, R133C, R294X, R306C, and 3’-trun-
cations result in less severity than other common
mutations (R106W, R168X, R255X, R270X, deletions/
insertions, and splice site mutations). Overall, clinical
severity tends to increase slowly with age as the result
of scoliosis, dystonia, and rigidity. Those who ambu-
late, maintain some hand function, and have a later
age at onset also tend to be less severely impacted.
However, markedly different clinical patterns or
outcomes can be seen in two females with exactly
the same genotype. These are most likely related
to differences in X-chromosome inactivation (XCI),
differing genetic backgrounds, environmental factors,
and the clonal distribution of normal and abnormal
X-chromosomes throughout the brain. From a rela-
tively small study in blood involving 183 participants
in the NHS (Friez et al., unpublished work), significant
skewing of XCI was noted, including 11% that were
highly skewed and 26% were moderately skewed.
Overall, 51% were random and 12% were uninforma-
tive. Of the 11% who were highly skewed, this was
evenly divided between the normal and the abnor-
mal X-chromosome and, thus, conferred an exclusive
advantage in neither direction.
Age at diagnosis
Considering the increasing potential for clinical tri-
als, earlier identification and diagnosis is regarded
as essential. Initially, the average age at diagnosis
was found to be greater than 4 years, but over the
course of the NHS, the average age has fallen, now
being 2.7 years [66]. In the US, the overwhelming per-
centage (90%) of diagnoses are made by child neu-
rologists, neuropediatricians, or geneticists. Regres-
sion was noted in 90% between age 12 years and
30 months. To increase diagnoses by primary care
physicians, certain clues can lead directly to diagno-
sis or to referral to a subspecialist. These include de-
clining head circumference in early infancy, declining
weight and height percentiles, slowing or plateauing
of development or frank regression, and the child ap-
pears to the parents to be “a really good baby”, that
is, the infant is “too good”. Greater attention to these
points could accelerate diagnosis.
Growth
Declining growth rates are typical [67–69]. First is the
declining head circumference growth rate, which may
be seen as early as 1.5 months with the median value
reaching the 2nd percentile by age 2 years. Weight, as
early as 6 months, and height, as early as 17 months,
follow, with the median values reaching the 2nd per-
centile by age 12 years [69]. Hands and feet are also
small, with the feet being relatively smaller [68].
Gastrointestinal features
Problems involving the gastrointestinal tract are seen
from top to bottom [70–73]. These include manipu-
lation of food in the mouth, swallowing issues, gas-
troesophageal reflux, delayed gastric emptying, con-
stipation, and gallbladder dysfunction. Food manipu-
lation in the mouth manifesting as prolonged feeding
times, gastroesophageal (G–E) reflux, and constipa-
tion are seen in the majority. Gallbladder dysfunction
is seen in about 3%, but has been seen as early as age
2–3 years. Given the inadequate ability to describe
pain, these issues deserve primary attention when the
individual is upset or unhappy, or awakens frequently
in the night. Gastrostomy tube placement provides
some or exclusive feeding in >30% [70].
Scoliosis
Scoliosis is present in the overwhelming majority of
girls by age 16 and in 8% of preschoolers, that is by
age 4 or earlier [74, 75]. Progression should cease at
maturity, but may increase slowly thereafter. Vary-
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ing degrees of severity are noted, usually by age 8.
The curvature is typically greater in the child who is
non-ambulatory and who has significant truncal hy-
potonia. Although no formal study has been done in
RTT, bracing is often considered with curves greater
than 25º. Surgery is recommended when the curve
exceeds 40º. In the NHS, 13% had surgery. Most par-
ents agreed that the quality of life was improved, both
for the individual and the family [75].
Prolonged QTc
Prolongation of the QTc interval is present in approx-
imately 20% of individuals in the NHS [76, 77]. While
this is generally in the borderline range, occasion-
ally it is sufficiently elevated to warrant treatment by
β-blockers. Rarely, QTc levels exceed 600 ms, in which
cases a pacemaker has been required. McCauley et al.
[77] demonstrated similar QTc prolongation in an an-
imal model of RTT and found that sodium channel
blockade was more effective than β-blockers. How-
ever, this has not been studied in humans.
Puberty and menarche
Puberty and menarche generally occur similar to typi-
cally developing females, but important differences do
exist [78]. Onset of puberty is premature in 25%, i.e.,
occurring before age 8 years, but the interval between
onset of puberty and menarche is longer than typical:
3.9 years vs. 3.0 years in typically developing females.
The median age for pubertal onset is shorter for breast
development and longer for pubic development by
about 6 months. Conversely, the age at menarche is
later than normal, age 13.0 vs. 12.5 years. The ear-
lier onset of puberty is correlated with increased body
mass index and the so-called milder mutations.
QOL for affected and caregivers
Quality of life (QOL) is an important component of
care for individuals with chronic disease and has
proven equally critical in RTT. Examining both cross-
sectional and longitudinal results from individuals
with RTT and their primary caregiver, typically the
mother, revealed that poor motor function is associ-
ated with greater clinical severity [79]. However, poor
motor function resulted in fewer behavioral problems
and conversely, better motor function resulted in
more behavioral issues. For example, those who were
ambulatory could climb on furniture, open doors and
leave the home, or injure themselves near a stove.
This raises the potential concern that modest im-
provement in motor function could result in greater
behavioral issues [79].
From the caregiver’s perspective, as the parents age
and may develop problems of their own, their physical
QOL declines, whereas mental QOL tends to improve
[80]. This is related to achieving an accommodation
with the issues associated with RTT and to the decline
in some interfering or concerning patterns such as
bruxism, periodic breathing, and general difficulties
in management. However, it is noted that once these
individuals age out of school, the availability of adult
programs may be significantly limited and will impact
the overall caregiving.
Survival
An initial analysis involving the NHS and the IRSA
registry demonstrated that survival in individuals
with RTT was normal through the first 10 years, but
declined significantly thereafter, with >75% alive at
age 30 and >50% at age 50, the latter being signifi-
cantly less than normal survival in US females [81].
However, when compared with the original group de-
scribed by Andreas Rett, overall longevity had at least
doubled [82]. This is related to improved diagnosis,
nutrition, physical and occupational therapies, and
overall management strategies.
Changing pattern of survival
Subsequently, a more recent examination of survival
and causation of death in the NHS confirmed the aver-
age survival beyond age 50, showing directly that pre-
served ambulation or assisted walking, maintenance
of adequate weight, and effective seizure control pro-
moted survival [83]. The extreme frailty reported in
the study of Kerr et al. in the 1990s was not seen in the
NHS in classic RTT. Death was often unwitnessed and
causation was difficult to determine, but cardiorespi-
ratory issues were regarded as the most likely cause
of difficulties. These results emphasize the positive
effects of diet and effective therapies.
Clinical trials
A number of clinical trials have been conducted, be-
ginning already in the era before the identification of
mutations in MECP2. The opiate antagonist naltrex-
one was assessed as a treatment for periodic breath-
ing. No benefit was noted, but the design of the trial
did not account for differing clinical severity between
the treatment and placebo groups, and could have
confounded the results [84]. However, it was shown in
a parallel study that the intravenous antagonist, nalox-
one, resulted in EEG slowing. Any beneficial effects
could have resulted merely from sedation. With the
identification of mutations in MECP2 and the poten-
tial role of DNA methylation, a trial of folate-betaine
was conducted in the early 2000s. Despite parent re-
ports of improvement, no positive objective evidence
was noted [85].
More recently, clinical trials have been conducted
with IGF-1 at Boston Children’s Hospital and with
NNZ-2566 (trofinetide), the terminal tripeptide of
IGF-1, at Baylor College of Medicine, UAB, and Gillette
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Children’s Hospital. Both agents proved to have no
significant safety or tolerability issues. The IGF-1
trial, based on a translational research study [86],
produced evidence of safety [87] and is continuing at
multiple sites. The NNZ-2566 trial in older girls and
women provided preliminary evidence of efficacy and
a second phase 2 trial is being conducted in children
aged 5–15 [88].
Other trials are in early stages of development or
enrollment. In a multisite trial, sarizotan, a serotonin
and dopamine receptor agonist, will be tested in girls
and women aged 13–50, and a trial with ketamine is
now starting at the Cleveland Clinic [89]. Both agents
are targeting the improvement of periodic breathing.
Future perspectives
In the more than 30 years that I have been involved
with Rett syndrome (RTT), remarkable progress has
been accomplished both clinically and in the labora-
tory. Improved management of individuals with RTT
and effective guidance not only in terms of medical
problems, but also with regard to proper nutrition,
therapeutic interventions, and the new and emerg-
ing field of augmentative communication using com-
puter-assisted strategies, have been beneficial. Tak-
ing the broader perspective for progress in RTT, the
energies of the international community at all lev-
els of research, from basic through translational to
clinical studies, are required. Many disease-modify-
ing strategies are advancing through translational re-
search and reaching the level of clinical trials. At the
same time, strategies to reverse the underlying ge-
netic defect are continuing, whether to replace the
defective gene or reverse X-chromosome inactivation.
These approaches do offer fundamental challenges
that must be overcome. The expansion of clinical
trials will require efforts of all, including the com-
mitment of funding agencies, pharmaceutical compa-
nies, researchers, patient advocacy groups, and fam-
ilies at the very least. Throughout the world, new
and more investigators must be recruited. Parent ad-
vocacy groups must continue to press for continued
progress. Clinical trials are essential, but are also labor
intensive, demand careful conduct, and require direct
participation of families and other caregivers. They re-
quire patience and courage, focus and understanding.
Above all, human involvement is a prerequisite. With-
out the involvement of everyone, the desired goals of
effective treatment and, ultimately, a cure, are an un-
achievable illusion.
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